Mydecine Innovations Group Inc.
MYCO.NE
Get informed when a big investor buys or sells
+ FollowMarket Cap$42.74M
Close$
$-0.12
132.9% downside
Current Fair Value
132.9% downsideOvervalued by 132.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $42.74 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | 2.29 |
| Outstanding Shares | 61,755,384 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -6.62 |
|---|---|
| PEG | 6.65 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Noveris Health Sciences Inc.
3 employees
CEO: Jason Birmingham Noveris Health Sciences Inc. operates as a biotechnology firm dedicated to the investigation, pharmaceutical development, and clinical evaluation of psilocybin-based products. Co-founded by Parente Carman, Damon Michaels, and Robert Rosc...